Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vir Biotechnology (VIR)
NASDAQ:VIR
Holding VIR?
Track your performance easily
VIR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.56 - $14.45
Previous CloseN/A
Volume25.73M
Average Volume (3M)2.82M
Market Cap
$1.46B
Enterprise Value$132.28M
Total Cash (Recent Filing)$187.92M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Feb 20, 2025EPS Estimate
-0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.92
Shares Outstanding137,720,120
10 Day Avg. Volume2,350,466
30 Day Avg. Volume2,818,932
Standard Deviation0.30
R-Squared0.00754
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)18.62
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.09
Enterprise Value/Revenue7.48
Enterprise Value/Gross Profit3.60
Enterprise Value/Ebitda-0.21
Forecast
1Y Price Target
$31.38Price Target Upside204.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Vir Biotechnology News
PremiumCompany Announcements
Vir Biotechnology Announces Leadership Change in 2025Bulls Say, Bears Say
Bulls Say
Financial Strength And FlexibilityVir has a strong balance sheet with a cash position sufficient to fund the company through multiple upcoming catalysts, providing operational flexibility.
Hepatitis Treatment ProgressVir is preparing to start multiple Phase 3 registrational trials for their hepatitis delta virus program, which is expected to drive momentum for the stock.
Oncology Treatment AdvancementsThe T cell engager (TCE) compounds are emerging as a potentially best-in-class approach for solid tumors, supported by early Phase 1 data demonstrating safety and anti-tumor activity.
Bears Say
Clinical TrialsThe proportion of participants with varying baseline HBsAg levels who achieved HBsAg loss at the end of treatment was notably lower at 16% for the doublet and 22% for the triplet regimen.
Financial PerformanceShares are expected to remain range-bound over the near- to mid-term due to concerns over the value-accretive potential from ongoing trial updates.
Strategic PartnershipsThe Vir/Sanofi deal appears more 'back-end loaded' compared to Sanofi's original acquisition, which investors think may imply prior development hurdles.
---
Ownership Overview
13.77% Insiders
13.20% Mutual Funds
0.04% Other Institutional Investors
51.76% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VIR FAQ
What was Vir Biotechnology’s price range in the past 12 months?
Vir Biotechnology lowest stock price was $6.56 and its highest was $14.45 in the past 12 months.
What is Vir Biotechnology’s market cap?
Vir Biotechnology’s market cap is $1.46B.
When is Vir Biotechnology’s upcoming earnings report date?
Vir Biotechnology’s upcoming earnings report date is Feb 20, 2025 which is in 19 days.
How were Vir Biotechnology’s earnings last quarter?
Vir Biotechnology released its earnings results on Oct 31, 2024. The company reported -$1.56 earnings per share for the quarter, missing the consensus estimate of -$1.052 by -$0.508.
Is Vir Biotechnology overvalued?
According to Wall Street analysts Vir Biotechnology’s price is currently Undervalued.
Does Vir Biotechnology pay dividends?
Vir Biotechnology does not currently pay dividends.
What is Vir Biotechnology’s EPS estimate?
Vir Biotechnology’s EPS estimate is -0.87.
How many shares outstanding does Vir Biotechnology have?
Vir Biotechnology has 137,720,120 shares outstanding.
What happened to Vir Biotechnology’s price movement after its last earnings report?
Vir Biotechnology reported an EPS of -$1.56 in its last earnings report, missing expectations of -$1.052. Following the earnings report the stock price went up 23.632%.
Which hedge fund is a major shareholder of Vir Biotechnology?
Among the largest hedge funds holding Vir Biotechnology’s share is Caxton Associates LP. It holds Vir Biotechnology’s shares valued at 534K.
---
Vir Biotechnology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.38 (204.36% Upside)
$31.38 (204.36% Upside)
Blogger Sentiment
Bullish
VIR Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 78.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $10.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 14.4%
Last 30 Days ▲ 14.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.38%
12-Months-Change
Fundamentals
Return on Equity
-36.58%
Trailing 12-Months
Asset Growth
-26.73%
Trailing 12-Months
Company Description
Vir Biotechnology
Vir Biotechnology, Inc. engages in the provision of technologies to treat and prevent infectious diseases. Its technology platforms include antibody, T cell, innate immunity, and siRNA. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in 2016 and is headquartered in San Francisco, CA.
---
VIR Company Deck
---
VIR Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted significant strategic achievements such as the licensing agreement with Sanofi and promising clinical trial results in the hepatitis delta program, which were somewhat offset by increased R&D expenses and decreased cash reserves due to the Sanofi transaction. Overall, the company's strategic moves suggest a strong potential for growth in the future.Read More>---
VIR Stock 12 Month Forecast
Average Price Target
$31.38
▲(204.36% Upside)
Technical Analysis
Best Analysts Covering VIR
1 Year
---